Request Sample Inquiry
Multiple Myeloma Market

Multiple Myeloma Market

Multiple Myeloma Market - Global Industry Assessment & Forecast

img
Healthcare
Number Of Pages # Pages:

147

Base Year:

2022

Date

May - 2023

Format:

PDF XLS PPT

Report Code:

VMR-2142

Segments Covered
  • By Drug Class By Drug Class Immunomodulators, Proteasome Inhibitor, Anti-CD38 Monoclonal Antibody, Alkylating Agents, Other Drug Classes
  • By Distribution Channel By Distribution Channel Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Pharmacies
  • By Region By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base YearBase Year: 2022
Forecast YearsForecast Years: 2023 - 2030
Historical YearsHistorical Years: 2017 - 2021
Revenue 2022Revenue 2022: USD 21.6 Billion
Revenue 2030Revenue 2030: USD 33.1 Billion
Revenue CAGRRevenue CAGR (2023 - 2030): 6.3%
Fastest Growing Region Fastest Growing Region (2023 - 2030) Asia Pacific
Largest Region Largest Region (2022): North America
Customization Offered
  • Cross-segment Market Size and Analysis for Mentioned Segments Cross-segment Market Size and Analysis for Mentioned Segments
  • Additional Company Profiles (Upto 5 With No Cost) Additional Company Profiles (Upto 5 With No Cost)
  • Additional Countries (Apart From Mentioned Countries) Additional Countries (Apart From Mentioned Countries)
  • Country/Region-specific Report Country/Region-specific Report
  • Go To Market Strategy Go To Market Strategy
  • Region Specific Market Dynamics Region Specific Market Dynamics
  • Region Level Market Share Region Level Market Share
  • Import Export Analysis Import Export Analysis
  • Production Analysis Production Analysis
  • Other Others Request Customization Speak To Analyst
  1. Executive Dashboard
    1. Strategic Imperatives
  2. Premium Insights
    1. Top 3 Trends to Watch
    2. Demand and Supply Trends
    3. Top 3 Strategies Followed by Major Players
    4. Top 3 Predictions by Vantage Market Research
    5. Top Investment Pockets
    6. Insights from Primary Respondents
  3. Global Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. Global Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. Global Multiple Myeloma Market - by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. Global Multiple Myeloma Market - by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. Global Multiple Myeloma Market - by region
      1. North America
      2. Europe
      3. Asia Pacific
      4. Latin America
      5. Middle East & Africa
    6. Market comparative analysis
  4. North America Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. North America Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. North America Multiple Myeloma Market, by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. North America Multiple Myeloma Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. North America Multiple Myeloma Market, by Country
      1. U.S.
        1. U.S. Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. U.S. Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      2. Canada
        1. Canada Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Canada Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      3. Mexico
        1. Mexico Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Mexico Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
  5. Europe Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. Europe Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. Europe Multiple Myeloma Market, by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. Europe Multiple Myeloma Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. Europe Multiple Myeloma Market, by Country
      1. Germany
        1. Germany Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Germany Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      2. UK
        1. UK Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. UK Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      3. France
        1. France Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. France Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      4. Spain
        1. Spain Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Spain Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      5. Italy
        1. Italy Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Italy Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      6. BENELUX
        1. BENELUX Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. BENELUX Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      7. Rest of Europe
        1. Rest Of Europe Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Rest Of Europe Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
  6. Asia Pacific Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. Asia Pacific Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. Asia Pacific Multiple Myeloma Market, by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. Asia Pacific Multiple Myeloma Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. Asia Pacific Multiple Myeloma Market, by Country
      1. China
        1. China Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. China Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      2. Japan
        1. Japan Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Japan Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      3. India
        1. India Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. India Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      4. South Korea
        1. South Korea Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. South Korea Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      5. South East Asia
        1. South East Asia Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. South East Asia Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      6. Rest of Asia Pacific
        1. Rest of Asia Pacific Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Rest of Asia Pacific Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
  7. Latin America Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. Latin America Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. Latin America Multiple Myeloma Market, by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. Latin America Multiple Myeloma Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. Latin America Multiple Myeloma Market, by Country
      1. Brazil
        1. Brazil Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Brazil Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      2. Argentina
        1. Argentina Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Argentina Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      3. Rest of Latin America
        1. Rest of Latin America Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Rest of Latin America Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
  8. Middle East & Africa Multiple Myeloma Market - Segment Analysis
    1. Overview
    2. Middle East & Africa Multiple Myeloma Market, 2016 - 2028 (USD Million)
    3. Middle East & Africa Multiple Myeloma Market, by Drug Class
      1. By Immunomodulators
      2. By Proteasome Inhibitor
      3. By Anti-CD38 Monoclonal Antibody
      4. By Alkylating Agents
      5. By Other Drug Classes
    4. Middle East & Africa Multiple Myeloma Market, by Distribution Channel
      1. By Hospital Pharmacies
      2. By Retail Pharmacies & Drug Stores
      3. By Online Pharmacies
    5. Middle East & Africa Multiple Myeloma Market, by Country
      1. GCC Countries
        1. GCC Countries Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. GCC Countries Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      2. South Africa
        1. South Africa Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. South Africa Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
      3. Rest of Middle East & Africa
        1. Rest of Middle East & Africa Multiple Myeloma Market, By Drug Class
          1. By Immunomodulators
          2. By Proteasome Inhibitor
          3. By Anti-CD38 Monoclonal Antibody
          4. By Alkylating Agents
          5. By Other Drug Classes
        2. Rest of Middle East & Africa Multiple Myeloma Market, By Distribution Channel
          1. By Hospital Pharmacies
          2. By Retail Pharmacies & Drug Stores
          3. By Online Pharmacies
  9. Key Market Dynamics
    1. Introduction
    2. Market Drivers
    3. Market Restraints
    4. Market Opportunities
    5. Porter's Five Forces Analysis
    6. PEST Analysis
    7. Regulatory Landscape
    8. Technology Landscape
    9. Regional Market Trends
  10. COVID 19 Impact Analysis
    1. Key strategies undertaken by companies to tackle COVID-19
    2. Short term dynamics
    3. Long term dynamics
  11. Marketing Stratagy Analysis
    1. Marketing Channel
    2. Direct Marketing
    3. Indirect Marketing
    4. Marketing Channel Development Trends
  12. Competative Landscape
    1. Competition Matrix - 2021
    2. Company Market Share Analysis - 2021
    3. Key Company Activities, 2018 - 2021
    4. Strategic Developments - Heat Map Analysis
    5. Company Offering Evaluation
    6. Company Regional Presence Evaluation
  13. Company Profiles
    1. Takeda Pharmaceutical Company Limited (Japan)
    2. Novartis AG (Switzerland)
    3. Teva Pharmaceutical Industries Ltd. (Israel)
    4. Bristol Myers Squibb Company (U.S.)
    5. Amgen Inc. (U.S.)
    6. ONO Pharmaceutical Co. Ltd. (Japan)
    7. Janssen Pharmaceuticals Inc. (Belgium)
    8. AbbVie Inc. (U.S.)
    9. Sanofi (Paris)
    10. Kary pharm (U.S.)
  14. Key Primary Respondents - VERBATIM
  15. Discussion Guide
  16. Customization Offered
  17. Annexure
  18. List of Figures
  19. List of Tables
  20. List of Abbreviations
Vantage Market Research | 24-May-2023
Multiple Myeloma Market to Reach Valuation of USD 33.1 Billion by 2030 – Growth in the Usage of Multiple Myeloma in Automotive Application Drives the Market
FAQ
Frequently Asked Question

  • The global Multiple Myeloma valued at USD 21.6 Billion in 2022 and is expected to reach USD 33.1 Billion in 2030 growing at a CAGR of 6.3%.

  • The prominent players in the market are Takeda Pharmaceutical Company Limited (Japan), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.), Amgen Inc. (U.S.), ONO Pharmaceutical Co. Ltd. (Japan), Janssen Pharmaceuticals Inc. (Belgium), AbbVie Inc. (U.S.), Sanofi (Paris), Kary pharm (U.S.).

  • The market is project to grow at a CAGR of 6.3% between 2023 and 2030.

  • The driving factors of the Multiple Myeloma include

    • Increasing Prevalence of Multiple Myeloma to Augment Market Growth

  • North America was the leading regional segment of the Multiple Myeloma in 2022.

Related Reports
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies Privacy Policy